[Lipoprotein regulatory effect of molsodomine in rats].
The antianginal drug N-ethoxycarbonyl-3-morpholinosydnonimine (molsidomine, Corvation) was orally administered (dose range 10(-5) - 10 mg/kg) to Wistar rats over 7 d once a day. The concentration of low density lipoprotein (LDL)-cholesterol in serum was decreased (40-45%) by therapeutic relevant dosages of molsidomine corresponding to an increase (80%) of the vasoprotective index high density lipoprotein (HDL)/LDL. HDL-cholesterol stayed unchanged. Clofibrate did not change the concentration of the lipoproteins in rat serum under equimolar conditions.
D000818:Animals; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000494:pharmacology; D008074:Lipoproteins / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008981:Molsidomine; D010069:Oxadiazoles / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D013558:Sydnones / Q000494:pharmacology*
D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D010069:Oxadiazoles; D013558:Sydnones; D002784:Cholesterol; D008981:Molsidomine; D002994:Clofibrate
Lipoprotein-regulatorische Wirkung von Molsidomin bei Ratten.